Information Provided By: 
Fly News Breaks for June 4, 2015
BLUE
Jun 4, 2015 | 09:11 EDT
After bluebird bio (BLUE) and Celgene (CELG) restricted their collaboration to only focus on multiple myeloma, Roth Capital says it had only assigned a value of $3 per share to the partnership, given its lack of visibility. The firm adds that the change may be a reflection of challenges with CART cancer treatments, but may also show bluebird's growing confidence in its own expertise. Roth keeps a Buy rating on bluebird and continues to identify it as a Focus Pick.
News For BLUE From the Last 2 Days
